№ lp_2_1_19884
File format: docx
Character count: 2462
File size: 19 KB
This document is an informed consent form for employees at risk of Hepatitis B exposure, explaining the voluntary nature of the vaccine and the related health information.
Year:
2013
Region / City:
North Central
Topic:
Hepatitis B vaccination
Document Type:
Informed consent form
Organization:
North Central Health Care
Author:
N/A
Target Audience:
Employees at risk of Hepatitis B exposure
Period of validity:
N/A
Approval Date:
N/A
Amendment Date:
N/A
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Note:
Year
Subject:
Viral Hepatitis
Document Type:
Health Department Report
Organization:
Kansas Health Department
Target Audience:
Healthcare providers
Year:
2025
Region / City:
United Kingdom
Subject:
Viral Hepatitis Management
Document Type:
Clinical Guideline
Author:
Lucy Garvey, Sanjay Bhagani, Ranjababu Kulasegaram, Michael Butler, Emma Hathorn, Paul Randal, Sarah Smith, Ryan White, Rachel Halford, Alison Grant, Giovanni Villa, Subathira Dakshina, Sema Mandal, Dan Bradshaw
Target Audience:
Healthcare professionals in sexual health and infectious diseases
Period of Validity:
2025
Approval Date:
July 21, 2025
Version:
1.2
Version Date:
July 21, 2025
Year:
2025
Region:
England
Subject:
Hepatitis B vaccination for renal patients
Document Type:
Patient Group Direction (PGD)
Authorising Organisation:
UK Health Security Agency (UKHSA)
Target Audience:
Registered healthcare professionals
Period of Validity:
28 February 2025 - 28 February 2028
Approval Date:
28 February 2025
Amendment Date:
21 February 2025
Note:
Year
Topic:
Hepatitis B Virus
Document Type:
Agent Summary
Organization / Institution:
U.S. Department of Health and Human Services, CDC, NIH
Target Audience:
Laboratory personnel, researchers
Description:
This document provides a detailed summary of the Hepatitis B virus, its characteristics, risks, transmission, diagnosis, and biosafety precautions for laboratory handling.
Year:
2018
Region / city:
Australia
Topic:
Immunisation, Hepatitis B
Document type:
Report
Agency / institution:
PBAC (Pharmaceutical Benefits Advisory Committee)
Author:
Chief Medical Officer
Target audience:
Healthcare professionals, policymakers
Period of validity:
Until 31 December 2019
Date of approval:
June 2018
Date of amendments:
None
Year:
2003
Region / city:
United States
Topic:
Hepatitis C, Clinical Reports, VISTA System
Document Type:
User Manual
Organization / Institution:
Department of Veterans Affairs
Author:
Not specified
Target Audience:
Local Coordinators, Managers, Clinicians
Period of Validity:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Context:
This user manual provides instructions for using the CPRS Query Tool for generating Hepatitis C-related clinical reports within the VISTA system.
Year:
2024
Region / city:
Australia
Theme:
Hepatitis B, Vaccination, Disease Surveillance
Document type:
Epidemiological review
Organ / institution:
Australian Government Department of Health
Authors:
Nicole Sonneveld, Joanne Jackson, Aditi Dey, Stephen Lambert, Katrina Clark, Benjamin Cowie, Kristine Macartney, Frank Beard
Target audience:
Researchers, health professionals, policymakers
Period of action:
2000–2019
Approval date:
24/06/2024
Date of changes:
N/A
Year:
2023
Region / city:
Not specified
Topic:
Hepatitis B, Hepatitis C, Public health
Document type:
Data collection form
Organization / institution:
Centers for Disease Control and Prevention (CDC)
Author:
Not specified
Target audience:
Healthcare professionals, Public health departments
Period of validity:
Not specified
Approval date:
Not specified
Date of amendments:
Not specified
Contextual description:
A form used to gather clinical and diagnostic data from patients with recent hepatitis B or C infections, without known risk factors, to assess potential healthcare exposure windows for further public health investigation.
Year:
2024
Region / City:
UK
Topic:
Hepatitis A, Public Health Surveillance
Document Type:
Questionnaire
Organization:
UKHSA
Authors:
Maya Gobin, Koye Balogun, Obaghe Edeghere
Target Audience:
Public Health Professionals, Healthcare Workers
Effective Period:
2024 - ongoing
Approval Date:
March 2024
Review Date:
April 2024
Version:
1.2
Last Modified:
March 2024
Year:
2023
Region / city:
England
Subject:
Vaccination, Hepatitis A
Document type:
Patient Group Direction (PGD)
Organization / institution:
UK Health Security Agency (UKHSA)
Author:
Christina Wilson, Dr. Sema Mandal, David Green
Target audience:
Healthcare practitioners
Period of validity:
31 October 2023 - 31 October 2026
Approval date:
5 October 2023
Review date:
31 March 2026
Expiry date:
31 October 2026
Version:
V5.00
Changes history:
Updated with new vaccine licensed for children, changes to vaccine administration routes
Description:
A PGD for the administration of the Hepatitis A vaccine to individuals at high risk, developed and authorised by UKHSA.
Year:
2015
Region / city:
Australia, New Zealand
Topic:
Hepatitis A virus inactivation in berries
Document type:
Guideline
Organization:
Food Standards Australia New Zealand, Ministry for Primary Industries
Author:
FSANZ Risk Assessment (Microbiology), Ministry for Primary Industries
Target audience:
Food manufacturers, food safety professionals
Period of validity:
Not specified
Approval date:
December 2015
Date of changes:
Not specified
Journal:
World Journal of Gastroenterology
Manuscript NO:
90838
Manuscript Type:
Letter to the Editor
Authors:
Francesca Colapietro, Nicola Pugliese, Antonio Voza, Alessio Aghemo, Stella De Nicola
Affiliations:
Department of Biomedical Sciences, Humanitas University, Milan, Italy; Division of Internal Medicine and Hepatology, Department of Gastroenterology, Humanitas Research Hospital, Milan, Italy; Department of Emergency, Humanitas Research Hospital, Milan, Italy
Corresponding Author:
Francesca Colapietro, MD, Department of Biomedical Sciences, Humanitas University, Milan, Italy, [email protected]
Received:
December 15, 2023
Revised:
January 11, 2024
Accepted:
February 18, 2024
Keywords:
Chronic hepatitis B, Reactivation, Nucleoside analogue, Tyrosine kinase inhibitors, Onco-hematology
Study Type:
Case report and literature review
Patient Details:
67-year-old Caucasian male with chronic lymphocytic leukemia, HBsAg-/anti-HBc+
Treatment:
Tyrosine kinase inhibitors, specifically acalabrutinib
Clinical Outcome:
HBV reactivation with liver failure, treated with nucleos(t)ide analogues
Year:
2010-2024
Region / city:
Asia-Pacific
Subject:
Hepatology
Document Type:
Clinical Practice Guidelines
Organization / Institution:
Asian Pacific Association for the Study of the Liver (APASL)
Author:
APASL
Target Audience:
Healthcare professionals
Period of validity:
2010-2024
Date of approval:
2010
Date of revisions:
2024
Context:
Collection of clinical practice guidelines and consensus statements issued by the Asian Pacific Association for the Study of the Liver on various hepatological conditions, including hepatocellular carcinoma, hepatitis B and C, liver transplantation, and metabolic diseases.
Year:
2012
Region / City:
Ukraine
Topic:
HCV treatment access, harm reduction, public health policy
Document Type:
Research paper
Organization / Institution:
Alliance
Author:
Ludmila Maistat, Pavlo Skala, Tatiana Barnard, Nataliia Kravchenko
Target Audience:
Public health professionals, policymakers, medical community
Period of Action:
2012 and ongoing
Date of Approval:
Not specified
Date of Changes:
Not specified
Description:
This document details the outcomes of large-scale advocacy and demonstration treatment programs aimed at improving access to HCV treatment for people who inject drugs (PWIDs) in Ukraine, with a focus on policy changes and the integration of HCV treatment into harm reduction programs.
Year:
Not applicable
Region / City:
Not applicable
Subject:
Research ethics and manuscript submission
Document Type:
Submission Template
Organization / Institution:
Not applicable
Author:
Not applicable
Target Audience:
Researchers, Authors submitting manuscripts
Period of validity:
Not applicable
Approval Date:
Not applicable
Date of Changes:
Not applicable
Note:
Year
Region / City:
Buffalo, NY
Topic:
Research Study Consent
Document Type:
Informed Consent Form
Institution:
University at Buffalo
Author:
University at Buffalo Research Compliance
Target Audience:
Research Participants
Year:
2016
Region / City:
United States
Topic:
Electronic Informed Consent (eIC)
Document Type:
Guidance
Agency / Institution:
Office for Human Research Protection (OHRP), Food and Drug Administration (FDA)
Author:
Office for Human Research Protection (OHRP), FDA
Target Audience:
Researchers, IRBs, Clinical Investigators, and Study Participants
Period of Validity:
Ongoing
Approval Date:
December 2016
Date of Revisions:
Not specified
Year:
2018
Region / City:
United States
Theme:
Cancer prevention, clinical trials
Document Type:
Template
Organ / Institution:
National Cancer Institute (NCI), National Institutes of Health (NIH)
Author:
NCI
Target Audience:
Researchers, clinical trial participants
Period of Validity:
Ongoing
Approval Date:
January 19, 2018
Date of Changes:
N/A
Note:
Year
Topic:
Human Subject Research
Document Type:
Informed Consent Form
Organization / institution:
Coastal Carolina University
Author:
[PI Name]
Target Audience:
Potential research participants